Matt Sagan: The Lancet Summary of the Next Generation of Cancer Vaccines
Matt Sagan, Founder, Managing Partner and CEO of MoD Partners and Executive Director of BioForum Accelerator, shared a post by The Lancet on X, adding:
“Great summary from The Lancet about the future of Cancer Immunotherapies with next generation of Cancer Vaccines in focus. We’ve learned a lot about vaccines, about cancer, about all science around both. Time to merge those 2!
We’re now probably facing next generation of cancer vaccines with Patients’ safety and well-being in focus coming in next 5-10 years.”
Quoting The Lancet‘s post:
““Vaccines have done more to improve public health than any other medical intervention.”
A Viewpoint focuses on cancer vaccines and the future of immunotherapy – analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve patient outcomes and quality of life.”
Title: Cancer vaccines and the future of immunotherapy
Authors: Orrin Pail, Matthew J Lin, Theodora Anagnostou, Brian D Brown, Joshua D Brody
More posts featuring Matt Sagan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023